Chiron Aredia sales will top $40 mil. this year, company tells analysts at Alex. Brown.
CHIRON AREDIA SALES WILL TOP $40 MIL. IN 1996, CEO Edward Penhoet told the Alex. Brown conference in Baltimore. Chiron markets Aredia (pamidronate) under a license from Ciba for hypercalcemia of malignancy, Paget's disease and osteolytic bone lesions of multiple myeloma.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth